Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules is a meticulously compounded medication, primarily used in the treatment of various inflammatory diseases such as ulcerative colitis, Crohn's disease, and proctitis. This unique formulation synergistically combines mesalamine, a potent anti-inflammatory agent, with sodium butyrate, a beneficial short-chain fatty acid. The result is a slow-release medication that ensures a steady and prolonged release of the active ingredients, thereby providing a consistent therapeutic effect over an extended period.

The encapsulation of these active ingredients is achieved using Methocel E4M, a specialized controlled-release polymer. This advanced technology is designed to gradually release the encapsulated medication, offering sustained therapeutic effects. This slow-release mechanism not only enhances the efficacy of the medication but also reduces the dosing frequency, thereby improving patient compliance, particularly for medications requiring a controlled and prolonged release profile.

Research has demonstrated the effectiveness of the combination of mesalamine and sodium butyrate in reducing inflammation and alleviating the symptoms associated with these inflammatory diseases. Furthermore, this formulation is generally well tolerated by patients, with minimal side effects reported.

At Bayview Pharmacy, we are dedicated to providing our patients with the highest quality compounded medications. We understand that each patient is unique, and therefore, we strive to provide personalized medication solutions to meet individual health needs. If you have any questions about this formulation or any other compounded medications, we encourage you to reach out to us. Our team of experienced pharmacists is always ready to assist you with your medication needs.

Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules is a compounded medication designed to treat conditions such as ulcerative colitis, Crohn's disease, and other inflammatory bowel diseases. The medication works by reducing inflammation in the intestines, providing relief from the symptoms associated with these conditions.

This formulation is encapsulated with Methocel E4M, a controlled-release polymer. This technology allows for the gradual release of the active ingredients over an extended period, providing sustained therapeutic effects. This slow-release mechanism can lead to reduced dosing frequency, potentially improving patient compliance, particularly for those requiring a controlled and prolonged release profile.

It is important to note that this medication is not recommended for use in children under the age of 18. Patients who are pregnant, planning to become pregnant, or breastfeeding should inform their healthcare provider before starting this medication. Additionally, patients should disclose any other medications they are currently taking, including prescription and over-the-counter medications, vitamins, and herbal supplements, as Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules may interact with other medications, including antacids, antibiotics, and diuretics.

Patients with a history of kidney disease, liver disease, or any other medical condition should not take Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules without first consulting their healthcare provider. It is also crucial to inform the healthcare provider of any allergies to any of the ingredients in this medication.

It is essential to take Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules exactly as prescribed by the healthcare provider. Patients should not alter the dosage or duration of the medication without professional medical advice. If you have any questions or concerns about this medication, please consult your healthcare provider.

Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules is a compounded formulation specifically designed for the treatment of ulcerative colitis, a type of inflammatory bowel disease. This combination medication works synergistically, with mesalamine reducing inflammation in the colon and sodium butyrate aiding in the reduction of inflammation and enhancing the absorption of mesalamine. The unique feature of this formulation is its slow-release mechanism, which is achieved through the use of Methocel E4M, a controlled-release polymer. This allows for the gradual release of the encapsulated medication over an extended period, providing sustained therapeutic effects and improved patient compliance. The reduced dosing frequency not only enhances the effectiveness of the treatment but also improves patient adherence to the medication regimen. The capsules are to be taken orally, with or without food, as per the doctor's instructions. It is crucial to adhere to the prescribed dosage and not to miss any doses to ensure the effectiveness of the treatment. Potential side effects may include nausea, vomiting, or abdominal pain. If any of these or other side effects occur, it is important to contact your healthcare provider immediately. This formulation is designed to provide a controlled and prolonged release profile, offering a more consistent and effective treatment for ulcerative colitis.

Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules are a compounded formulation designed to provide sustained therapeutic effects over an extended period of time. This is achieved through the use of Methocel E4M, a controlled-release polymer that gradually releases the encapsulated medication or active ingredient. This slow-release mechanism reduces the need for frequent dosing and improves patient compliance, particularly for medications that require a controlled and prolonged release profile.

This formulation is primarily used in the treatment of inflammatory bowel diseases such as ulcerative colitis. However, it may also be beneficial in managing other conditions such as microscopic colitis, pouchitis, and ischemic colitis. Furthermore, it has potential applications in the treatment of radiation colitis, ulcerative jejunoileitis, and Behcet's disease.

Beyond gastrointestinal disorders, Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules may also be used in the management of certain rheumatic conditions. These include ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. However, it is important to note that this formulation is not recommended for use in children under the age of 18.

If you have any questions about the use of this formulation for any of these conditions, it is recommended to consult with a healthcare professional. They can provide guidance based on your specific health situation and needs.